Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Sanoculis Ltd. logo — Sanoculis offers MIMS®, Minimally Invasive Micro Sclerostomy...

Sanoculis Ltd.

Sanoculis offers MIMS®, Minimally Invasive Micro Sclerostomy, a novel, stent-less straightforward Glaucoma surgery.

Founded 2012 Israel Israel 11 employees Series C Health Care, Manufacturing +1

General Information

Company Name Sanoculis Ltd.
Founded Year 2012
Location Israel Israel
Employees 11
Industries Health Care, Manufacturing, Medical Devices
Funding Stage Series C
Social

BounceWatch is an independent company data service, not affiliated with Sanoculis Ltd.. To contact Sanoculis Ltd., visit sanoculis.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About Sanoculis Ltd.

Sanoculis Ltd. is an Israeli startup founded in 2012, specializing in the health care, manufacturing, and medical devices industries. The company's flagship offering, MIMS® (Minimally Invasive Micro Sclerostomy), is a pioneering, stent-less solution for Glaucoma surgery, aimed at creating a drainage channel to reduce intraocular pressure in Glaucoma patients. By offering a straightforward surgical procedure without the need for stitches, eye-patches, implants, or stents, Sanoculis aims to lower caring costs for Glaucomatous patients through simplicity, cost-efficiency, decreased post-surgical complications, and minimized hospitalization. The technology behind MIMS® not only represents a novel approach to Glaucoma treatment but also offers several key advantages, including its stent-less nature, which reduces the risk of complications. Additionally, the solution can be easily combined with Cataract surgery and is medication-sparing, thereby improving patients' quality of life. Sanoculis recently received a Series C investment on 25 January 2023, with Eckuity Capital and DNV Capital participating as investors. This funding round reflects a strong investor confidence in the company's innovative approach to addressing the needs of Glaucoma patients and improving the efficacy and accessibility of Glaucoma treatment.

Taxonomy: Glaucoma surgery, Minimally Invasive Surgery, Ophthalmology, Medical Technology, Medication-sparing, Cataract surgery integration, Intraocular pressure, Sclerostomy procedure, Healthcare Innovation, Patient Quality of Life

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Series C Undisclosed 2
Eckuity Capital
Eckuity Capital, DNV capital
25 Jan 2023

Sanoculis Ltd. Alternatives & Competitors

View All Alternatives
Sanoculis Ltd. vs
Rheon Medical
Rheon Medical Switzerland

Rheon focuses on the development, manufacturing and marketing of first-in-class glaucoma drainage de...

Debt Financing
7 employees
Health Care, Health and Wellness
Sanoculis Ltd. vs
Atia Vision
Atia Vision United States

Atia Vision is a portfolio company of Shifamed, LLC, a highly-specialized medical innovation hub foc...

Venture round
34 employees
Biotechnology, Health Care
Sanoculis Ltd. vs
IQ Medical Pty Ltd
IQ Medical Pty Ltd Australia

Delivering comprehensive intraocular solutions and pre-surgical services for optimal cataract care.

21 employees
Fashion, Health Care
View all alternatives

FAQ About Sanoculis Ltd.

Sanoculis offers MIMS®, Minimally Invasive Micro Sclerostomy, a novel, stent-less straightforward Glaucoma surgery.
Sanoculis Ltd. was founded in 2012.
Sanoculis Ltd. is headquartered in Israel.
Sanoculis Ltd. operates in Health Care, Manufacturing and Medical Devices. Its work centres on Glaucoma surgery, Minimally Invasive Surgery, Ophthalmology and Medical Technology.
Sanoculis Ltd. has approximately 11 employees.
Sanoculis Ltd. has completed 1 funding round. The latest funding stage is Series C.
Top alternatives and competitors to Sanoculis Ltd. include Rheon Medical, Atia Vision, IQ Medical Pty Ltd, Elios Vision, Galil Medical Ltd.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Sanoculis Ltd. and Rheon Medical are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Sanoculis Ltd., https://bouncewatch.com/company/sanoculis-ltd, updated 24 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes